title: A multidimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia: I. Comparisons with healthy control subjects and neuroleptic-treated/unmedicated pairs analyses.
abstract: Recent hypotheses and findings indicate that measurements of interactions between cerebrospinal fluid (CSF) biogenic amine systems, rather than measurement of CSF biogenic amine metabolites, better correlate with clinically important findings in schizophrenia. To test hypotheses, we used a recent technological advance in high performance liquid chromatography with electrochemical detection and combined it with multivariate statistical analyses to study biogenic amine concentrations in CSF in schizophrenia. This approach enabled the study of the interactions of several metabolites of each of the three major neurotransmitter pathways (dopaminergic, noradrenergic, and serotonergic) to test existing hypotheses regarding the neurobiochemical basis of schizophrenia. Twenty biogenic amines, their metabolites, and other compounds from 24 medication-free schizophrenic patients and 12 normal control subjects were simultaneously measured using a recently developed technique of gradient high performance liquid chromatography coupled with a 16-channel electrochemical array detector. After covariation for storage time, results of a stepwise discriminant function analysis comparing the control and patient groups identified tryptophan, tryptophol, and epinephrine as discriminating variables. Hotelling's paired T2 test from a subgroup of schizophrenic patients studied while they were and were not receiving neuroleptic treatment did not yield any significant differences between subgroups. A discussion of the findings and a comparison with previous studies of CSF biogenic amines in schizophrenia are presented.
authors.affiliation: Neuropsychiatry Branch, National Institute of Mental Health, Washington, DC 20032.
authors.forename: F
authors.initials: F
authors.lastname: Issa
authors.forename: G A
authors.initials: GA
authors.lastname: Gerhardt
authors.forename: J J
authors.initials: JJ
authors.lastname: Bartko
authors.forename: R L
authors.initials: RL
authors.lastname: Suddath
authors.forename: M
authors.initials: M
authors.lastname: Lynch
authors.forename: P H
authors.initials: PH
authors.lastname: Gamache
authors.forename: R
authors.initials: R
authors.lastname: Freedman
authors.forename: R J
authors.initials: RJ
authors.lastname: Wyatt
authors.forename: D G
authors.initials: DG
authors.lastname: Kirch
mesh_terms: D000328:Adult; D001679:Biogenic Amines / Q000134:cerebrospinal fluid*; D002851:Chromatography, High Pressure Liquid; D002908:Chronic Disease; D004298:Dopamine / Q000134:cerebrospinal fluid; D004311:Double-Blind Method; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use*; D006801:Humans; D007737:Kynurenine / Q000134:cerebrospinal fluid; D008297:Male; D009638:Norepinephrine / Q000134:cerebrospinal fluid; D012559:Schizophrenia / Q000134:cerebrospinal fluid / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D012701:Serotonin / Q000134:cerebrospinal fluid; D014364:Tryptophan / Q000134:cerebrospinal fluid; D014443:Tyrosine / Q000134:cerebrospinal fluid
chemical_list: D001679:Biogenic Amines; D012701:Serotonin; D007737:Kynurenine; D014443:Tyrosine; D014364:Tryptophan; D006220:Haloperidol; D004298:Dopamine; D009638:Norepinephrine